343 related articles for article (PubMed ID: 35105685)
21. Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
Bigaut K; Fabacher T; Kremer L; Ongagna JC; Kwiatkowski A; Sellal F; Ferriby D; Courtois S; Vermersch P; Collongues N; Zéphir H; De Seze J; Outteryck O
Mult Scler; 2021 Apr; 27(5):729-741. PubMed ID: 32643521
[TBL] [Abstract][Full Text] [Related]
22. Functional Disability and Brain MRI Volumetry Results among Multiple Sclerosis Patients during 5-Year Follow-Up.
Strautmane S; Balodis A; Teivane A; Grabovska D; Naudins E; Urbanovics D; Fisermans E; Mednieks J; Flintere-Flinte A; Priede Z; Millers A; Zolovs M
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374286
[No Abstract] [Full Text] [Related]
23. Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups.
Samson RS; Cardoso MJ; Muhlert N; Sethi V; Wheeler-Kingshott CA; Ron M; Ourselin S; Miller DH; Chard DT
Mult Scler; 2014 Sep; 20(10):1322-30. PubMed ID: 24552746
[TBL] [Abstract][Full Text] [Related]
24. Deep gray matter changes in relapsing-remitting multiple sclerosis detected by multi-parametric, high-resolution magnetic resonance imaging (MRI).
Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
Eur Radiol; 2021 Feb; 31(2):706-715. PubMed ID: 32851443
[TBL] [Abstract][Full Text] [Related]
25. Network Damage Predicts Clinical Worsening in Multiple Sclerosis: A 6.4-Year Study.
Rocca MA; Valsasina P; Meani A; Pagani E; Cordani C; Cervellin C; Filippi M
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34021055
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal Fluid-In Gradient of Cortical and Deep Gray Matter Damage in Multiple Sclerosis.
Rubin M; Pagani E; Preziosa P; Meani A; Storelli L; Margoni M; Filippi M; Rocca MA
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200271. PubMed ID: 38896808
[TBL] [Abstract][Full Text] [Related]
27. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
[TBL] [Abstract][Full Text] [Related]
28. Chronic lesion activity and disability progression in secondary progressive multiple sclerosis.
Beynon V; George IC; Elliott C; Arnold DL; Ke J; Chen H; Zhu L; Ke C; Giovannoni G; Scaramozza M; Campbell N; Bradley DP; Franchimont N; Gafson A; Belachew S
BMJ Neurol Open; 2022; 4(1):e000240. PubMed ID: 35720980
[TBL] [Abstract][Full Text] [Related]
29. Spinal cord volume loss: A marker of disease progression in multiple sclerosis.
Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K
Neurology; 2018 Jul; 91(4):e349-e358. PubMed ID: 29950437
[TBL] [Abstract][Full Text] [Related]
30. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
[TBL] [Abstract][Full Text] [Related]
31. Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis.
Giorgio A; Stromillo ML; Bartolozzi ML; Rossi F; Battaglini M; De Leucio A; Guidi L; Maritato P; Portaccio E; Sormani MP; Amato MP; De Stefano N
Mult Scler; 2014 Feb; 20(2):214-9. PubMed ID: 23877971
[TBL] [Abstract][Full Text] [Related]
32. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
[TBL] [Abstract][Full Text] [Related]
33. Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Hao Q; Kanda M; Tani Y
BMC Neurol; 2023 Aug; 23(1):311. PubMed ID: 37644415
[TBL] [Abstract][Full Text] [Related]
34. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients.
Cavallari M; Palotai M; Glanz BI; Egorova S; Prieto JC; Healy BC; Chitnis T; Guttmann CR
Mult Scler; 2016 Dec; 22(14):1841-1849. PubMed ID: 26920374
[TBL] [Abstract][Full Text] [Related]
35. Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.
Río J; Rovira À; Tintoré M; Otero-Romero S; Comabella M; Vidal-Jordana Á; Galán I; Castilló J; Arrambide G; Nos C; Tur C; Pujal B; Auger C; Sastre-Garriga J; Montalban X
Mult Scler; 2018 Mar; 24(3):322-330. PubMed ID: 28287331
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
37. Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32817406
[TBL] [Abstract][Full Text] [Related]
38. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
[TBL] [Abstract][Full Text] [Related]
39. Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study.
Calabrese M; Filippi M; Rovaris M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Grossi P; Barachino L; Rinaldi L; Romualdi C; Perini P; Gallo P
Mult Scler; 2009 Jan; 15(1):36-41. PubMed ID: 18755823
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal patterns of cortical thinning in multiple sclerosis.
Tsagkas C; Chakravarty MM; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Magon S
Hum Brain Mapp; 2020 Jun; 41(8):2198-2215. PubMed ID: 32067281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
